CHRISTOPHER WRAIGHT

CEO & Director

Christopher has more than 20 years’ experience in early-stage pharmaceutical R&D and commercialisation in companies financed by both public and private equity.
He was Research Director and a technology founder at ASX-listed Antisense Therapeutics Ltd, an Ionis Pharmaceuticals satellite company.  Christopher has guided RNA-targeting drugs from research through to the clinic and commercial exit.
As CEO, he navigated a small molecule nasal spray product from concept through Phase 1b and exit in 5 years at Otifex, and he built a company structure and team that made the most advanced direct Myc inhibitor for cancer at MycRx. 
Christopher has a PhD in Biochemistry and an MBA specialising in Technology Management.  He was a Guest Scientist and Humboldt Fellow at the German Cancer Research Centre in Heidelberg, and in 2008 he received the Advance BioBusiness Award for leadership in the Australian Life Sciences sector.

077CC580-1EAD-472B-BEA3-725FB2869DE7_edited_edited.jpg